公开(公告)号：US20230390291A1

公开(公告)日：2023-12-07

申请号：US18453355

申请日：2023-08-22

Applicant: Sol-Gel Technologies Ltd.

Inventor： Moshe ARKIN ,  Marcel ZIGHELBOIM ,  Ori NOV ,  Ofer TOLEDANO ,  Karine NEIMANN

IPC: A61K31/517 ,  A61P35/00 ,  A61K9/00

CPC classification number: A61K31/517 ,  A61P35/00 ,  A61K9/0014

Abstract: Provided herein compositions and methods of treatment of skin or mucosal disorders by administration of compositions comprising at least one EGFR inhibitor, such as topical compositions comprising erlotinib. The compositions of this invention are useful for the treatment, prevention or amelioration of skin or mucosal disorders like psoriasis, palmoplantar psoriasis, acquired palmoplantar keratosis, eczema, ichthyosis vulgaris, non-melanoma skin cancer, actinic keratosis, a keratinization skin disorder, a keratinization mucosal disorder, pachyonychia congenita, hidradenitis suppurativa, Gorlin syndrome, prurigo nodularis and prurigo pigmentosa.

公开(公告)号：US20200261402A1

公开(公告)日：2020-08-20

申请号：US16794974

申请日：2020-02-19

Applicant: Sol-Gel Technologies Ltd.

Inventor： Ofer TOLEDANO ,  Ofra LEVY-HACHAM ,  Ori NOV ,  Vered RAM

IPC: A61K31/327 ,  A61P17/00

Abstract: A regimen for the therapeutic treatment of moderate to severe erythema symptoms in rosacea patients, the regimen comprising topically applying to the skin of a subject in need of said treatment a pharmaceutical composition, the pharmaceutical composition comprising about 1% w/w to about 10% w/w benzoyl peroxide as an active ingredient, and a pharmaceutically acceptable carrier or excipient, wherein the benzoyl peroxide is the only active ingredient in said pharmaceutical composition, wherein said pharmaceutical composition is applied once daily for a period of at least about 12 weeks, to achieve a percentage decrease of about 60% in a population exhibiting moderate to severe erythema symptoms when measured at about 12 weeks after initial treatment of the population with the pharmaceutical composition.

公开(公告)号：US20220362204A1

公开(公告)日：2022-11-17

申请号：US17869210

申请日：2022-07-20

Applicant: Sol-Gel Technologies Ltd.

Inventor： Ofer TOLEDANO ,  Ofra LEVY-HACHAM ,  Ori NOV ,  Vered RAM

IPC: A61K31/327 ,  A61P17/10 ,  A61K9/00 ,  A61K9/06 ,  A61K9/107 ,  A61P17/00 ,  A61K9/50 ,  A61K9/10

Abstract: A regimen for the long-term therapeutic treatment of rosacea. The regimen includes topically applying to the skin of a subject in need of said treatment a pharmaceutical composition. The pharmaceutical composition includes about 1% w/w to about 10% w/w benzoyl peroxide as an active ingredient, and a pharmaceutically acceptable carrier or excipient. The benzoyl peroxide is the only active ingredient in said pharmaceutical composition, and the pharmaceutical composition is applied once daily for a period of up to about 40 weeks to about 52 weeks, to achieve, in a group of such subjects, a success rate of about 75% to about 85%.

公开(公告)号：US20210346380A1

公开(公告)日：2021-11-11

申请号：US17352322

申请日：2021-06-20

Applicant: Sol-Gel Technologies Ltd.

Inventor： Moshe ARKIN ,  Marcel ZIGHELBOIM ,  Ori NOV ,  Ofer TOLEDANO ,  Karine NEIMANN ,  Asher Cachlon

IPC: A61K31/517 ,  A61K9/00 ,  A61K45/06

Abstract: This invention relates to compositions and methods of treatment of skin or mucosal disorders by administration of compositions comprising at least one EGFR inhibitor, such as topical compositions comprising erlotinib. The compositions of this invention are useful for the treatment, prevention or amelioration of skin or mucosal disorders like psoriasis, palmoplantar psoriasis, acquired palmoplantar keratosis, eczema, ichtyosis vulgaris, non-melanoma skin cancer, actinic keratosis, a keratinization skin disorder, a keratinization mucosal disorder, pachyonychia congenita, hidradenitis suppurativa, Gorlin syndrome, prurigo nodularis and prurigo pigmentosa.

公开(公告)号：US20210283093A1

公开(公告)日：2021-09-16

申请号：US17202394

申请日：2021-03-16

Applicant: Sol-Gel Technologies Ltd.

Inventor： Ori NOV ,  Karine NEIMANN ,  Asher CACHLON

IPC: A61K31/327 ,  A61K9/00 ,  A61K45/06 ,  A61K9/06 ,  A61P33/00

Abstract: The present invention relates to the treatment, prevention or alleviation of a gastrointestinal disorder caused by one or more intestinal helminths, said treatment, prevention or alleviation comprises administering a topical composition comprising a peroxide to a subject in need thereof.

公开(公告)号：US20230248687A1

公开(公告)日：2023-08-10

申请号：US18123702

申请日：2023-03-20

Applicant: Sol-Gel Technologies Ltd.

Inventor： Ofer TOLEDANO ,  Ori NOV

IPC: A61K31/327 ,  A61K9/00 ,  A61K9/50 ,  A61K9/06 ,  A61P17/00

CPC classification number: A61K31/327 ,  A61K9/06 ,  A61K9/0014 ,  A61K9/50 ,  A61P17/00

Abstract: A regimen and a pharmaceutical composition for the treatment of a skin condition and/or skin affliction are described. The regimen includes topically applying to the skin of a subject in need of such treatment a pharmaceutical composition comprising about 2.5% w/w to about 10% w/w benzoyl peroxide as an active ingredient, and a pharmaceutically acceptable carrier or excipient.

公开(公告)号：US20220287990A1

公开(公告)日：2022-09-15

申请号：US17629424

申请日：2020-07-23

Applicant: Sol-Gel Technologies Ltd.

Inventor： Moshe ARKIN ,  Marcel ZIGHELBOIM ,  Ori NOV ,  Ofer TOLEDANO

IPC: A61K31/05 ,  A61K9/00 ,  A61K31/327 ,  A61K31/519 ,  A61K31/203 ,  A61K31/192 ,  A61K31/4436 ,  A61K31/4709 ,  A61K31/65 ,  A61K31/7056 ,  A61K31/7048 ,  A61K9/06

Abstract: Provided herein is a topical combination composition and a method of treatment of an inflammatory skin condition by administration of said composition comprising at least one Janus kinase inhibitor (JAK inhibitor) and at least one additional active agent elected from benzoyl peroxide (BPO), at least one retinoid, tapinarof, at least one antibiotic, at least one antiandrogen, at least one acaricide and combinations thereof and a carrier suitable for topical administration. The JAK inhibitor and the at least one additional active agent exhibit an additive or synergistic effect, allowing to reduce the amounts of active agents in the composition.

公开(公告)号：US20200261401A1

公开(公告)日：2020-08-20

申请号：US16794923

申请日：2020-02-19

Applicant: Sol-Gel Technologies Ltd

Inventor： Ofer TOLEDANO ,  Ofra LEVY-HACHAM ,  Ori NOV ,  Vered RAM

IPC: A61K31/327 ,  A61P17/00 ,  A61K9/00 ,  A61K9/06 ,  A61K9/10 ,  A61K9/50

Abstract: A regimen is described for the therapeutic treatment of rosacea including topically applying to the skin of a subject in need of the treatment a pharmaceutical composition. The pharmaceutical composition includes about 1% w/w to about 10% w/w benzoyl peroxide as an active ingredient, and a pharmaceutically acceptable carrier or excipient. The benzoyl peroxide is the only active ingredient in said pharmaceutical composition, and the pharmaceutical composition is applied once daily for a period of at least about 2 weeks, about 4 weeks, about 8 weeks or about 12 weeks. A decrease in Patient Assessment of Papulopustular Rosacea Signs and Symptoms (PAPSS) is at least about 40% after treatment with the pharmaceutical composition for about 4 weeks, and a decrease in Patient Assessment of Papulopustular Rosacea Impacts (PAPI) is from about 60% to about 70% after treatment with the pharmaceutical composition for at least about 8 weeks.

公开(公告)号：US20190015370A1

公开(公告)日：2019-01-17

申请号：US16033257

申请日：2018-07-12

Applicant: SOL-GEL TECHNOLOGIES LTD.

Inventor： Ofer TOLEDANO ,  Ori NOV

IPC: A61K31/203 ,  A61K9/00 ,  A61K31/327 ,  A61K9/50 ,  A61P17/10

CPC classification number: A61K31/203 ,  A61K9/0014 ,  A61K9/006 ,  A61K9/501 ,  A61K31/327 ,  A61P17/10

Abstract: The present application is directed to regimens, methods of treatment, and compositions for the treatment of acne in a subject suffering therefrom

公开(公告)号：US20230364050A1

公开(公告)日：2023-11-16

申请号：US18225397

申请日：2023-07-24

Applicant: Sol-Gel Technologies Ltd.

Inventor： Ofer TOLEDANO ,  Ofra LEVY-HACHAM ,  Ori NOV ,  Vered RAM

IPC: A61K31/327 ,  A61K9/50 ,  A61K9/06 ,  A61K9/00 ,  A61P17/10 ,  A61K9/107 ,  A61P17/00 ,  A61K9/10

CPC classification number: A61K31/327 ,  A61K9/50 ,  A61K9/06 ,  A61K9/0014 ,  A61P17/10 ,  A61K9/107 ,  A61P17/00 ,  A61K9/10

Abstract: A regimen is described for the therapeutic treatment of rosacea including topically applying to the skin of a subject in need of the treatment a pharmaceutical composition. The pharmaceutical composition includes about 1% w/w to about 10% w/w benzoyl peroxide as an active ingredient, and a pharmaceutically acceptable carrier or excipient. The benzoyl peroxide is the only active ingredient in said pharmaceutical composition, and the pharmaceutical composition is applied once daily for a period of at least about 2 weeks, about 4 weeks, about 8 weeks or about 12 weeks. A decrease in Patient Assessment of Papulopustular Rosacea Signs and Symptoms (PAPSS) is at least about 40% after treatment with the pharmaceutical composition for about 4 weeks, and a decrease in Patient Assessment of Papulopustular Rosacea Impacts (PAPI) is from about 60% to about 70% after treatment with the pharmaceutical composition for at least about 8 weeks.